The Mifepristone Case and the Legitimacy of the FDA

JAMA. 2023 Jun 27;329(24):2121-2122. doi: 10.1001/jama.2023.8712.
No abstract available

Plain language summary

This Viewpoint discusses a recent federal court decision that invaliated the Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to end pregnancies and manage miscarriage when used with misoprostol, and how that decision challenges the legitimacy and independence of the FDA.

MeSH terms

  • Abortion, Induced*
  • Female
  • Humans
  • Mifepristone*
  • Misoprostol*
  • Pregnancy
  • United States
  • United States Food and Drug Administration / legislation & jurisprudence

Substances

  • Mifepristone
  • Misoprostol